Results 81 to 90 of about 8,267,225 (310)

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall [PDF]

, 2018
Benign TdT-positive cells have been documented in a variety of non-hematopoietic tissues. Scant data are however available on their presence in non-neoplastic lymph nodes.
AGOSTINELLI, CLAUDIO, Bertuzzi, Clara, BRIGNOLA, STEFANO, Pillon, Marta, Pizzi, Marco, Righi, Simona, Rugge, Massimo, Sabattini, Elena, Semenzato, Gianpietro   +8 more
core   +1 more source

Prevalence of neoplasms in patients with acromegaly – the need for a national registry

Annals of Agricultural and Environmental Medicine, 2018
Introduction Acromegaly is an endocrine disorder caused predominantly by pituitary adenoma leading to autonomic oversecretion of growth hormone and secondary elevation of insulin-like growth factor 1 (IGF-1).
Beata Matyjaszek-Matuszek, Ewa Obel, Marcin Lewicki, Jolanta Kowalczyk-Bołtuć, Agata Smoleń   +4 more
doaj   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

P608: THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.

HemaSphere, 2023
Lluís Hernández, Ferran Nadeu, Julio Delgado, Martí Duran-Ferrer, Dario Rafael Romero, Ruth Orellana Fernández, Tamara Bittolo, Riccardo Bomben, Valter Gattei, Elias Campo   +9 more
doaj   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

MicroRNA expression profiles in pediatric dysembryoplastic neuroepithelial tumors. [PDF]

, 2016
© Springer Science+Business Media New York 2015Among noncoding RNAs, microRNAs (miRNAs) have been most extensively studied, and their biology has repeatedly been proven critical for central nervous system pathological conditions.
A Ranger, A Spalice, A Tessitore, B Zhang, C Wang, DK Birks, DN Louis, E Ferretti, E. Kanavakis, F Chassoux, F Ozlen, F Wang, G Cui, G Della Vittoria Scarpati, G. I. Lambrou, I Qaddoumi, J Cai, J Qiao, K Yao, K. Stefanaki, M Braoudaki, M Braoudaki, M Li, M Maschio, M Thom, M Wang, M. Braoudaki, N. Prodromou, P Zhou, R Kunder, S Lu, S Vella, S. A. Papadodima, SB Ng, TM Brinkman, X Zhang, Z Jamali   +36 more
core   +2 more sources

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Feline vestibular disorders. Part II: diagnostic approach and differential diagnosis. [PDF]

, 1999
Results of a neurological examination usually permit localisation of a vestibular disorder to either the central or peripheral parts of the vestibular system. Many different disorders located in the same part of the vestibular system will produce similar
LeCouteur, RA, Vernau, KM
core  

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms [PDF]

, 2015
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,
Aranaz, P., Aranaz, P., Bandinelli, S., Bandinelli, S., Barosi, G., Barosi, G., Baxter, E.J., Baxter, E.J., Callaway, A., Callaway, A., Campbell P., Campbell P., Cazzola, M., Cazzola, M., Chase, A., Chase, A., Chen, E., Chen, E., Cross N.C., Cross N.C., Dohner, K., Dohner, K., Duncombe, A.S., Duncombe, A.S., Evans, P., Evans, P., Ewing, J., Ewing, J., Gale, R.E., Gale, R.E., Giannopoulos, A., Giannopoulos, A., Gisslinger, H., Gisslinger, H., Godfrey, A.L., Godfrey, A.L., Grallert, H., Grallert, H., Green, A.R., Green, A.R., Griffiths, M., Griffiths, M., Guglielmelli, P., Guglielmelli, P., Haferlach, T., Haferlach, T., Harrison, C., Harrison, C., Harutyunyan, A.S., Harutyunyan, A.S., Jack, A., Jack, A., Jones, A.V., Jones, A.V., Kralovics, R., Kralovics, R., Leung, W., Leung, W., Lin, F., Lin, F., Maclean, C., Maclean, C., Mannarelli, C., Mannarelli, C., Mead, A.J., Mead, A.J., Nangalia, J., Nangalia, J., Oscier, D., Oscier, D., Pieri, L., Pieri, L., Reiter, A., Reiter, A., Schnittger, S., Schnittger, S., Schuh, A., Schuh, A., Short, M., Short, M., Stegelmann, F., Stegelmann, F., Strauch, K., Strauch, K., Tanaka, T., Tanaka, T., Tapper, W., Tapper, W., Vannucchi, A., Vannucchi, A., Waghorn, K., Waghorn, K., Wallis, L., Wallis, L., Ward, D., Ward, D., White, H.E., White, H.E., Zoi, K., Zoi, K.   +99 more
core   +5 more sources